Clinical Trials Logo

Clinical Trial Summary

Current prenatal diagnosis of placenta accrete spectrum disorders relies on subjective individual interpretations of visual sonographic findings on grayscale and color Doppler imaging. When blinded to clinical data, there is significant interobserver variability in the diagnosis of invasive placentation. This study will evaluate placental thickness among pregnant women with placenta previa and determine if increased placenta thickness correlates with the risk for placenta accreta spectrum (PAS) disorders.


Clinical Trial Description

Placenta accreta spectrum is one of the most dangerous conditions associated with pregnancy, because hemorrhage may result in multisystem organ failure, disseminated intravascular coagulation, need for admission to an intensive care unit, hysterectomy, and even death. The reported incidence of placenta accrete spectrum disorder has increased over time and is currently between 1 in 533 to 1 in 300 pregnancies. Prior cesarean delivery and especially multiple cesarean deliveries are major risk factors. The spectrum includes placenta accreta (attachment of the placenta to myometrium without intervening decidua), placenta increta (invasion of the trophoblast into the myometrium), and placenta percreta (invasion through the myometrium, serosa, and into surrounding structures). PAS is linked to placenta previa, and there is a lot of overlap in imaging findings between the two processes. PAS problems affect approximately 11% of people with placenta previa. Differentiating between placenta previa with and without PAS problems is crucial in clinical practice. A finding of placenta previa together with a history of cesarean delivery has long been an indication for counseling patients on their risk of PAS in a current pregnancy, as the risk for placenta accreta in the presence of placenta previa increases with each subsequent cesarean delivery. Aside from cesarean deliveries and placenta previa, other risk factors have been identified for PAS, including past uterine surgeries, in vitro fertilization (IVF), multiparity, maternal age, and even female sex of the infant. Prenatal diagnosis of AIP has been shown to reduce maternal morbidity associated with this condition, most likely due to the opportunity to plan management in advance. Ultrasound is the primary investigation for prenatal diagnosis of morbidly adherent placenta, and the diagnostic accuracy is good both in retrospective, as well as prospective case series. Placental localization with transabdominal sonography (TAS) has been a standard practice for a long time. Despite its availability and noninvasive nature, accuracy of TAS may be limited by many factors, such as the posterior implantation of placenta, being obscured by the fetal head, an under-filled or over-distended bladder, and presence of blood clots, fibroids, uterine contractions, and obesity. These limitations are overcome by transvaginal sonography (TVS), which provides a better resolution by using a higher frequency transducer, shorter distance from the transducer to the internal os, and is not affected by the over- or under-filling of the bladder. Although ultrasonography's sensitivity and specificity for detecting accreta have been reported to be excellent, ranging from 80 to 90%, there was considerable difference among "experts" in predicting whether PAS was present. With placental implantation into the cesarean section scar, the center of the placental disc would be in the vicinity of the lower uterine scar. If placental implantation was near the scar but not in it, only the thinner placental margin might encroach into the lower uterine segment. The investigators therefore hypothesized that the placenta is thicker with AIP in women with a low-lying placenta or placenta previa. So, the investigators hypothesize that placental thickness will be directly related to placental invasion in cases of placenta accrete spectrum. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05500404
Study type Observational
Source Ain Shams Maternity Hospital
Contact
Status Completed
Phase
Start date December 1, 2021
Completion date August 31, 2022

See also
  Status Clinical Trial Phase
Withdrawn NCT04927988 - Blood Components Changes by Using of Ringer's Lactated as Detergent In Autologous Blood Cell Transfusion N/A
Not yet recruiting NCT04525001 - MOGGE PAR Scores for Prediction of Outcomes of PAS
Completed NCT04427592 - New Conservative Technique for Placenta Accreta Spectrum N/A
Completed NCT04314791 - Accuracy of Placenta Accreta Index in Diagnosing Placenta Accreta Spectrum
Completed NCT06356493 - Prophylactic Occlusion Balloons of Both Internal Iliac Arteries in Caesarean Hysterectomy for PASD
Recruiting NCT06383923 - Risk Factors, Prognosis and Prediction Models for Placenta Accreta Without Prior Cesarean Section
Recruiting NCT05752513 - Early vs Late Bladder Dissection During CS Hysterectomy in Patients With PAS With Bladder Invasion N/A
Not yet recruiting NCT04229953 - Accuracy of Three /Four-dimensional Ultrasound in Diagnosing Placenta Accreta Spectrum
Recruiting NCT05510076 - Evaluation of Different Surgical Approaches Used for Conservative Management of Placenta Accreta Spectrum in Sohag University Hospital
Not yet recruiting NCT05481606 - Cesarean Scar Pregnancy and Clinical Outcomes
Recruiting NCT04866888 - Placenta Accreta Spectrum Outcome After Uterine Conservation N/A